Compared to the disappointing rabbit hybridoma technology which generally indicates low stability and productivity, Creative Biolabs’ guinea pig hybridoma technique develops a novel source of outbreeding non-murine immune repertoire with comparatively stable productivity.
Guinea pig, which is suggested as domesticated descendants of a closely related species of cavy, is a kind of rodent that does not exist naturally in the wild. It is one of the earliest species that has been applied in the field of research and investigation for more than 20 decades. However, as the genetic research of guinea pig (such as guinea pig antibody) has fallen behind during the early 20th century, it becomes less popular than mice and rats in a variety of research (such as humanized mice antibody). Even though, it is still an ideal source to generate antibodies for extreme allergic reactions or anaphylaxis research. It is also treated as an important model for the study of various infectious diseases, such as tuberculosis and diphtheria.
With the development of guinea pig genome sequencing, this species seems to restore its attraction as a novel source of monoclonal antibody. A typical development of guinea pig antibody is the high affinity anti-human insulin monoclonal antibodies, which are hardly obtained from mouse and rat immune response because of their higher insulin homology with human. According to these properties, guinea pigs are considered with huge potential to generate novel target-specific monoclonal antibodies for a series of research and therapeutic studies.
Creative Biolabs offers unique guinea pig hybridoma technology to generate monoclonal guinea pig antibodies. Through fusing with our specific myeloma as partner, guinea pig hybridoma can be developed with excellent stability and productivity.
“Our scientists are confident in developing guinea pig hybridoma that produces monoclonal antibody with high affinity and specificity”, said Dr. Monika, scientific officer of Creative Biolabs.
About Creative Biolabs
Creative Biolabs is specialized in providing custom biotechnology and pharmaceutical services that cover the full scope of biotechnology needs of early antibody drug discovery and development.